首页> 外文期刊>Medical Devices: Evidence and Research >A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression
【24h】

A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression

机译:对迷走神经刺激疗法治疗难治性抑郁症的研究进行的患者水平荟萃分析

获取原文
           

摘要

Objective: To compare response and remission rates in depressed patients with chronic treatment-resistant depression (TRD) treated with vagus nerve stimulation (VNS) Therapy? plus treatment as usual (VNS + TAU) or TAU alone in a meta-analysis using Bayesian hierarchical models.Data sources and study selection: Six outpatient, multicenter, clinical trials that have evaluated VNS + TAU or TAU in TRD, including two single-arm studies of VNS + TAU (n = 60 and n = 74), a randomized study of VNS + TAU versus TAU (n = 235), a randomized study of VNS + TAU comparing different VNS stimulation intensities (n = 331), a nonrandomized registry of VNS + TAU versus TAU (n = 636), and a single-arm study of TAU (n = 124) to provide longer-term, control data for comparison with VNS-treated patients.Data extraction: A systematic review of individual patient-level data based on the intent-to-treat principle, including all patients who contributed more than one post-baseline visit. Response was based on the Montgomery–?sberg Depression Rating Scale (MADRS) and the Clinical Global Impressions scale's Improvement subscale (CGI-I), as these were the two clinician-rated measures common across all or most studies. Remission was based on the MADRS.Results: Outcomes were compared from baseline up to 96 weeks of treatment with VNS + TAU (n = 1035) versus TAU (n = 425). The MADRS response rate for VNS + TAU at 12, 24, 48, and 96 weeks were 12%, 18%, 28%, and 32% versus 4%, 7%, 12%, and 14% for TAU. The MADRS remission rate for VNS + TAU at 12, 24, 48, and 96 weeks were 3%, 5%, 10%, and 14% versus 1%, 1%, 2%, and 4%, for TAU. Adjunctive VNS Therapy was associated with a greater likelihood of response (odds ratio [OR] = 3.19, 95% confidence interval [CI]: 2.12, 4.66) and remission (OR = 4.99, CI: 2.93, 7.76), compared with TAU. For patients who had responded to VNS + TAU at 24 weeks, sustained response was more likely at 48 weeks (OR = 1.98, CI: 1.34, 3.01) and at 96 weeks (OR = 3.42, CI: 1.78, 7.31). Similar results were observed for CGI-I response.Conclusion: For patients with chronic TRD, VNS + TAU has greater response and remission rates that are more likely to persist than TAU.
机译:目的:比较迷走神经刺激(VNS)疗法治疗的慢性耐药性抑郁症(TRD)抑郁症患者的反应和缓解率?资料来源和研究选择:六项门诊,多中心,临床试验评估了TRD中的VNS + TAU或TAU,包括两项单项, VNS + TAU的分组研究(n = 60和n = 74),VNS + TAU与TAU的随机研究(n = 235),VNS + TAU比较不同VNS刺激强度的随机研究(n = 331), VNS + TAU与TAU的非随机注册表(n = 636),以及TAU的单臂研究(n = 124),以提供长期的对照数据,以便与VNS治疗的患者进行比较。基于意向治疗原则的单个患者水平数据,包括所有在基线后就诊超过一次的患者。反应基于蒙哥马利?伯格抑郁评定量表(MADRS)和临床总体印象量表的改进子量表(CGI-I),因为这是所有或大多数研究中常见的两个临床医生评定量度。结果:比较了从基线到VNS + TAU(n = 1035)与TAU(n = 425)治疗至96周的结果。 VNS + TAU在12、24、48和96周的MADRS响应率分别为12%,18%,28%和32%,而TAU分别为4%,7%,12%和14%。 VNS + TAU在12、24、48和96周时的MADRS缓解率分别为3%,5%,10%和14%,而TAU分别为1%,1%,2%和4%。与TAU相比,辅助性VNS疗法具有更大的反应可能性(优势比[OR] = 3.19,95%置信区间[CI]:2.12、4.66)和缓解(OR = 4.99,CI:2.93、7.76)。对于在24周时对VNS + TAU有反应的患者,在48周(OR = 1.98,CI:1.34,3.01)和96周(OR = 3.42,CI:1.78,7.31)时,持续缓解的可能性更高。结论:对于慢性TRD患者,VNS + TAU比TAU具有更高的反应和缓解率,并且更可能持续。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号